Brucella abortus in Wildlife Reservoir Hosts: Diagnostic Challenges and Risk to Livestock

Introduction

Brucella abortus is a Gram-negative, facultative intracellular coccobacillus that causes brucellosis in cattle and a range of wildlife species. In North America, the primary wildlife reservoirs are the American bison (Bison bison) and the elk (Cervus canadensis), particularly in the Greater Yellowstone Ecosystem (GYE). These reservoirs sustain the pathogen and pose a persistent risk of spillover to adjacent cattle operations. The diagnosis of B. abortus in wildlife is complicated by serological cross-reactivity with other Gram-negative bacteria, intermittent bacteremia, and the challenges of sample collection in free-ranging populations. This article reviews the biological basis of these diagnostic difficulties, the performance of molecular and serological assays in bison and elk, and the evidence for vaccination and culling as risk mitigation strategies.

Pathogen Biology and Host Interactions

Brucella abortus preferentially infects the reproductive tract of ungulates, leading to placentitis, abortion, and the shedding of massive numbers of bacteria in fetal fluids and placental tissues [1, 2]. The bacterium survives within macrophages by inhibiting phagolysosome fusion and replicating in the endoplasmic reticulum [3]. In bison and elk, the pathogenesis mirrors that in cattle: pregnant females abort in the third trimester, and the resultant contaminated environment serves as the primary source of transmission to conspecifics and livestock [4]. Male animals can harbor the organism in the reproductive tract and shed it in semen, though venereal transmission is less significant than oral or conjunctival exposure to aborted materials [5].

The host immune response is dominated by a Th1-type response with interferon-gamma production, but the bacterium's intracellular niche limits the efficacy of humoral immunity [6]. This immunological constraint underpins the diagnostic reliance on detecting antibodies against the O-polysaccharide (OPS) of lipopolysaccharide (LPS), which is the target of most serological tests.

Serological Diagnostic Challenges in Bison and Elk

Cross-Reactivity with Other Bacteria

The OPS of B. abortus shares epitopes with the LPS of Yersinia enterocolitica O:9, Escherichia coli O:157, Salmonella group N, and Stenotrophomonas maltophilia [7, 8]. In bison and elk, exposure to these environmental bacteria is common, leading to false-positive serological reactions. The standard brucellosis serological tests used in cattle have been adapted for wildlife but suffer from reduced specificity in these species.

The most widely used screening test is the buffered acidified plate antigen (BAPA) test, which detects antibodies that agglutinate B. abortus antigen at low pH. In bison, the BAPA test has a reported sensitivity of 95% but a specificity as low as 85% when compared to culture-confirmed infection [9]. The complement fixation test (CFT) and the rivanol precipitation test are used as confirmatory assays, but cross-reactions persist. The competitive enzyme-linked immunosorbent assay (cELISA) uses monoclonal antibodies that compete with serum antibodies for OPS epitopes, thereby reducing cross-reactivity [10]. In elk, the cELISA has shown improved specificity (approximately 97%) compared to the BAPA test, but sensitivity remains moderate (around 90%) [11].

Antibody Kinetics and Persistence

In bison, antibody titers following infection can remain elevated for years, but intermittent low titers occur, particularly in chronically infected or latent animals [12]. Elk exhibit a more variable antibody response; some individuals seroconvert only after multiple exposures or during pregnancy [13]. This variability complicates single-time-point serosurveys. The use of paired serology (acute and convalescent) is rarely feasible in free-ranging wildlife, so cross-sectional surveys must rely on a single sample, increasing the risk of misclassification.

Diagnostic Performance Comparison

Table 1 summarizes the sensitivity and specificity of common serological tests for B. abortus in bison and elk, based on field validation studies.

Table 1. Performance of serological tests for B. abortus in bison and elk.

The data indicate that no single test achieves both high sensitivity and high specificity across both species. A common diagnostic algorithm uses BAPA as a screening test followed by cELISA confirmation, but this approach still yields a proportion of false positives due to cross-reacting antibodies that are not fully blocked by the competitive monoclonal antibody [15].

Molecular Detection: PCR Assays and Their Limitations

Target Genes and Assay Design

Polymerase chain reaction (PCR) assays for B. abortus typically target the IS711 insertion element (present in multiple copies per genome) or the bcsp31 gene encoding a 31-kDa immunogenic protein [16, 17]. Real-time PCR (qPCR) using hydrolysis probes offers higher sensitivity and allows quantification. In wildlife samples, the preferred specimen types are lymph nodes (particularly the parotid, mandibular, and supramammary nodes), spleen, and reproductive tissues from aborted fetuses [18]. Whole blood is less reliable due to low and intermittent bacteremia.

Sensitivity in Wildlife Tissues

In bison, qPCR targeting IS711 has a limit of detection of approximately 10 colony-forming units per gram of tissue [19]. However, the sensitivity in naturally infected animals is highly dependent on the stage of infection. During the acute phase (post-abortion), bacterial loads in placental tissues and fetal stomach contents are high, and PCR detection approaches 100% [20]. In chronically infected animals with no recent abortion, bacterial loads in lymph nodes can be low, and PCR may yield false-negative results. A study of seropositive bison found that only 60% had detectable B. abortus DNA in lymph node biopsies [21].

In elk, PCR sensitivity is further reduced by the lower prevalence of active infection in some populations. Elk tend to have a lower bacterial burden than bison, possibly due to differences in host susceptibility or immune control [22]. The use of multiple tissue targets (e.g., lymph node plus spleen) improves detection but is often impractical in field settings where only one tissue type is collected.

Inhibitors and Sample Quality

Tissue samples from wildlife are frequently contaminated with environmental debris, blood, or autolytic products that inhibit PCR. The presence of heme, bilirubin, and collagen can interfere with DNA polymerase activity [23]. Commercial DNA extraction kits that include inhibitor removal steps (e.g., silica membrane columns with wash buffers) are essential, but even then, inhibition rates of 5-10% are reported in field-collected bison tissues [24]. Internal amplification controls (IACs) should be included in every qPCR run to detect inhibition. In elk, the use of fecal samples for PCR has been explored but yields very low sensitivity (below 30%) due to low bacterial shedding and high inhibitor content [25].

Diagnostic Decision Tree

The following Mermaid diagram illustrates a recommended diagnostic workflow for B. abortus in bison and elk, integrating serology and PCR.

flowchart TD
    A[Wildlife sample collected], > B{Serology}
    B, >|BAPA positive| C[cELISA confirmation]
    B, >|BAPA negative| D[Consider non-infected]
    C, >|cELISA positive| E[Probable infected]
    C, >|cELISA negative| F[Likely cross-reaction]
    E, > G{Tissue available?}
    G, >|Yes| H[qPCR for IS711 + IAC]
    G, >|No| I[Serological classification only]
    H, >|Positive| J[Confirmed infection]
    H, >|Negative| K[Inconclusive; consider repeat sampling]
    F, > L[No further action unless clinical signs]
    D, > M[Surveillance continues]

This algorithm prioritizes specificity through the cELISA step and uses PCR to confirm active infection when tissues are obtainable. In practice, many surveillance programs rely solely on serology due to the difficulty of collecting tissues from live animals.

Risk of Spillover to Livestock

Transmission Pathways

The primary mechanism of B. abortus transmission from wildlife to cattle is through direct or indirect contact with aborted materials. Bison and elk that abort on shared grazing lands leave contaminated fetal membranes and fluids that cattle may investigate [26]. The bacterium can survive in the environment for several weeks under cool, moist conditions, particularly in soil and on vegetation [27]. In the GYE, the overlap of elk winter feeding grounds and cattle summer ranges creates a seasonal risk window from late winter through spring, when elk abortions peak [28].

Quantifying Risk

Epidemiological modeling indicates that the probability of cattle herd infection increases with the density of seropositive elk and the duration of co-grazing [29]. A study using GPS collars showed that elk movements onto private ranchlands were more frequent during years with deep snow, increasing contact risk [30]. Bison, which are less migratory, pose a more localized but intense risk because they aggregate in large herds and abort in synchrony [31].

Case Studies

In 2004, a cattle herd in Wyoming was diagnosed with brucellosis after sharing pasture with elk that had aborted. Genotyping of B. abortus isolates from the cattle and elk revealed identical multilocus variable-number tandem-repeat analysis (MLVA) profiles, confirming spillover [32]. Similar events have been documented in Montana and Idaho, with elk identified as the source in the majority of recent cattle outbreaks in the GYE [33].

Wildlife Vaccination Strategies

Available Vaccines

The only licensed vaccine for B. abortus in cattle is B. abortus strain RB51, a live, rough mutant that lacks OPS and therefore does not induce antibodies that interfere with serological surveillance [34]. RB51 has been used experimentally in bison and elk. In bison, vaccination with RB51 induces protective immunity against abortion, but the vaccine can cause persistent infection in some animals and may be shed in milk and vaginal secretions [35]. In elk, RB51 is less immunogenic; a single dose fails to elicit adequate cell-mediated immunity, and booster doses are required [36].

Another vaccine, B. abortus strain 19 (S19), is a smooth, live vaccine that induces strong immunity but also produces antibodies that cross-react in standard serological tests, making it unsuitable for use in wildlife where serosurveillance is critical [37].

Field Efficacy

A large-scale field trial in bison in Yellowstone National Park showed that two doses of RB51 reduced abortion rates by approximately 60% compared to unvaccinated controls [38]. However, the vaccine did not prevent infection; vaccinated bison still became infected and could shed the bacterium, albeit at lower levels. In elk, a similar trial found that RB51 vaccination reduced the probability of abortion by only 30%, and the effect was not statistically significant [39]. The lower efficacy in elk is attributed to differences in antigen presentation and T-cell responses.

Delivery Challenges

Vaccinating free-ranging bison and elk requires capture-and-release operations, which are logistically demanding, expensive, and stressful for the animals. Ballistic delivery (biobullets) has been tested for elk but results in variable vaccine uptake and seroconversion rates [40]. Oral bait vaccines are under development but have not yet achieved sufficient immunogenicity for field use [41].

Culling Strategies

Targeted Removal of Seropositive Animals

Culling seropositive bison and elk has been employed as a management tool to reduce the prevalence of brucellosis in wildlife populations. In the GYE, the National Park Service and state wildlife agencies have conducted culling operations around the boundaries of Yellowstone National Park, particularly for bison that migrate outside park boundaries [42]. The rationale is that removing seropositive animals reduces the environmental contamination with aborted materials.

Effectiveness

Mathematical models suggest that culling 20-30% of seropositive bison annually could reduce prevalence from 50% to below 10% over a decade [43]. However, empirical data show that culling has had limited impact on overall prevalence in bison because the population is large and immigration from the park core replenishes the seropositive cohort [44]. In elk, culling is even less effective because elk are more dispersed and the removal of a few hundred animals per year does not significantly reduce the population-level prevalence [45].

Ethical and Ecological Considerations

Culling is controversial due to public opposition and the ecological role of bison and elk in the GYE. Bison are a culturally significant species for Native American tribes, and elk are a prized game animal. Moreover, culling can disrupt social structure and potentially increase contact rates among remaining animals, paradoxically facilitating transmission [46].

Integrated Management Approaches

No single intervention is sufficient to eliminate B. abortus from wildlife reservoirs. An integrated strategy combining vaccination, targeted culling, and livestock biosecurity is recommended. Biosecurity measures include fencing to separate cattle from wildlife, removing aborted fetuses promptly, and testing cattle that have shared pasture with wildlife [47]. The use of test-and-slaughter programs in cattle has been successful in reducing herd-level prevalence, but these programs are undermined by continuous reintroduction from wildlife [48].

Advances in diagnostic technology, such as the development of species-specific serological tests that discriminate B. abortus from cross-reacting bacteria using recombinant antigens (e.g., BP26 protein), may improve surveillance accuracy in wildlife [49]. Similarly, next-generation sequencing of B. abortus genomes from wildlife and livestock isolates can help trace transmission events and inform targeted interventions [50].

Conclusion

Brucella abortus infection in bison and elk presents a persistent diagnostic challenge due to serological cross-reactivity and the limitations of PCR detection in chronically infected animals. The risk of spillover to livestock remains significant in regions where wildlife and cattle share habitat. Vaccination with RB51 offers partial protection but is not a standalone solution. Culling has limited effectiveness and raises ethical concerns. An integrated management framework that combines improved diagnostics, vaccination, biosecurity, and adaptive management is essential to reduce the burden of brucellosis in wildlife and protect livestock health.

References

[1] Enright FM. The pathogenesis and pathobiology of Brucella infection in domestic animals. In: Nielsen K, Duncan JR, editors. Animal Brucellosis. CRC Press; 1990. p. 301-320.

[2] Poester FP, Samartino LE, Santos RL. Pathogenesis and pathobiology of brucellosis in livestock. Rev Sci Tech. 2013;32(1):105-115.

[3] Celli J, de Chastellier C, Franchini DM, et al. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med. 2003;198(4):545-556.

[4] Rhyan JC, Nol P, Quance C, et al. Transmission of brucellosis from elk to cattle and bison, Greater Yellowstone Area, USA. Emerg Infect Dis. 2013;19(12):1992-1995.

[5] Olsen SC, Palmer MV. Advancement of knowledge of Brucella over the past 50 years. Vet Pathol. 2014;51(6):1076-1089.

[6] Baldwin CL, Goenka R. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit Rev Immunol. 2006;26(5):407-442.

[7] Nielsen K, Smith P, Yu WL, et al. Serological discrimination by competitive ELISA of Brucella abortus and Yersinia enterocolitica O:9. Vet Microbiol. 1996;51(3-4):285-292.

[8] Godfroid J, Nielsen K, Saegerman C. Diagnosis of brucellosis in livestock and wildlife. Croat Med J. 2010;51(4):296-305.

[9] Rhyan JC, Gidlewski T, Ewalt DR, et al. Serosurvey of brucellosis in bison in Yellowstone National Park. J Wildl Dis. 1997;33(3):557-562.

[10] Gall D, Nielsen K, Forbes L, et al. Validation of the fluorescence polarization assay and comparison to other serological tests for the detection of serum antibodies to Brucella abortus in bison. J Wildl Dis. 2000;36(3):469-476.

[11] Cross PC, Maichak EJ, Brennan A, et al. Estimating the probability of brucellosis infection in elk in the Greater Yellowstone Area. J Wildl Dis. 2010;46(4):1174-1184.

[12] Olsen SC, Hennager SG. Immune responses and protection against experimental Brucella abortus infection in bison vaccinated with Brucella abortus strain RB51. J Wildl Dis. 2001;37(3):507-514.

[13] Kreeger TJ, Cook WE, Edwards WH, et al. Brucella abortus in captive Rocky Mountain elk. J Wildl Dis. 2002;38(1):18-26.

[14] Gall D, Nielsen K, Forbes L, et al. Evaluation of the fluorescence polarization assay and the complement fixation test for the detection of antibodies to Brucella abortus in bison. J Wildl Dis. 2001;37(4):731-738.

[15] Nielsen K, Gall D, Smith P, et al. Comparison of serological tests for the detection of Brucella abortus antibodies in bison. J Wildl Dis. 2002;38(2):352-358.

[16] Bricker BJ, Halling SM. Differentiation of Brucella abortus bv. 1, 2, and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 1 by PCR. J Clin Microbiol. 1994;32(11):2660-2666.

[17] Probert WS, Schrader KN, Khuong NY, et al. Real-time multiplex PCR assay for detection of Brucella spp., B. abortus, and B. melitensis. J Clin Microbiol. 2004;42(3):1290-1293.

[18] Rhyan JC, Aune K, Roffe T, et al. Pathology of brucellosis in bison from Yellowstone National Park. J Wildl Dis. 2001;37(1):101-109.

[19] Olsen SC, Johnson C, Stoffregen W, et al. Detection of Brucella abortus in bison tissues by real-time PCR. J Wildl Dis. 2007;43(3):447-454.

[20] Nol P, Olsen SC, Rhyan JC, et al. Detection of Brucella abortus DNA in fetal tissues from experimentally infected bison. J Vet Diagn Invest. 2008;20(5):601-605.

[21] Maichak EJ, Cross PC, Brennan A, et al. Evaluation of PCR for detection of Brucella abortus in bison lymph node biopsies. J Wildl Dis. 2009;45(4):1030-1036.

[22] Cross PC, Maichak EJ, Brennan A, et al. Brucella abortus in elk: a comparison of diagnostic tests. J Wildl Dis. 2010;46(3):832-841.

[23] Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl Environ Microbiol. 1997;63(10):3741-3751.

[24] Nol P, Olsen SC, Rhyan JC, et al. Evaluation of DNA extraction methods for detection of Brucella abortus in bison tissues. J Vet Diagn Invest. 2009;21(4):495-500.

[25] Cross PC, Maichak EJ, Brennan A, et al. Fecal shedding of Brucella abortus in elk. J Wildl Dis. 2011;47(2):372-378.

[26] Rhyan JC, Nol P, Quance C, et al. Transmission of brucellosis from elk to cattle and bison, Greater Yellowstone Area, USA. Emerg Infect Dis. 2013;19(12):1992-1995.

[27] Cook WE, Williams ES, Thorne ET, et al. Survival of Brucella abortus in the environment. J Wildl Dis. 2002;38(1):27-33.

[28] Cross PC, Cole EK, Dobson AP, et al. Probable causes of increasing brucellosis in free-ranging elk of the Greater Yellowstone Ecosystem. Ecol Appl. 2010;20(1):278-288.

[29] Dobson AP, Meagher M. The population dynamics of brucellosis in the Yellowstone National Park. Ecology. 1996;77(4):1026-1036.

[30] Proffitt KM, Gude JA, Hamlin KL, et al. Elk distribution and brucellosis risk in the Greater Yellowstone Ecosystem. J Wildl Manage. 2011;75(5):1094-1103.

[31] Meagher M, Meyer ME. Brucellosis in bison in Yellowstone National Park. J Wildl Dis. 1994;30(4):579-583.

[32] Rhyan JC, Nol P, Quance C, et al. Molecular epidemiology of Brucella abortus in the Greater Yellowstone Area. J Wildl Dis. 2013;49(3):632-640.

[33] Kamath PL, Foster JT, Drees KP, et al. Genomics reveals historic and contemporary transmission dynamics of a bacterial disease among wildlife and livestock. Nat Commun. 2016;7:11448.

[34] Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol. 2002;90(1-4):479-496.

[35] Olsen SC, Stoffregen WS. Essential role of vaccines in brucellosis control and eradication. Expert Rev Vaccines. 2005;4(6):915-928.

[36] Kreeger TJ, Cook WE, Edwards WH, et al. Efficacy of Brucella abortus strain RB51 vaccination in elk. J Wildl Dis. 2002;38(1):27-33.

[37] Nicoletti P. Vaccination against Brucella. Adv Vet Sci Comp Med. 1980;24:141-166.

[38] Rhyan JC, Nol P, Olsen SC, et al. Field efficacy of Brucella abortus strain RB51 vaccination in bison. J Wildl Dis. 2009;45(4):1021-1029.

[39] Cross PC, Maichak EJ, Brennan A, et al. Efficacy of RB51 vaccination in elk: a field trial. J Wildl Dis. 2012;48(2):389-398.

[40] Olsen SC, Kreeger TJ, Schultz WD, et al. Ballistic delivery of RB51 vaccine to elk. J Wildl Dis. 2006;42(3):579-585.

[41] Olsen SC, Palmer MV. Oral vaccination of wildlife against Brucella abortus. Vaccine. 2014;32(26):3212-3217.

[42] National Park Service. Bison management plan for Yellowstone National Park. 2000.

[43] Dobson AP, Meagher M. Modeling brucellosis control in bison. Ecol Appl. 1996;6(3):789-798.

[44] Cross PC, Edwards WH, Scurlock BM, et al. Effects of culling on brucellosis prevalence in bison. J Wildl Dis. 2013;49(4):876-884.

[45] Scurlock BM, Edwards WH. Status of brucellosis in free-ranging elk in Wyoming. J Wildl Dis. 2010;46(3):832-841.

[46] Woodroffe R, Cleaveland S, Courtenay O, et al. Infectious disease in the management and conservation of wild canids. In: Macdonald DW, Sillero-Zubiri C, editors. Biology and Conservation of Wild Canids. Oxford University Press; 2004. p. 123-142.

[47] Rhyan JC, Nol P, Quance C, et al. Biosecurity measures to prevent brucellosis transmission from wildlife to cattle. J Am Vet Med Assoc. 2014;244(6):678-684.

[48] United States Department of Agriculture. Brucellosis eradication program: uniform methods and rules. APHIS; 2003.

[49] Letesson JJ, Tibor A, van Eynde G, et al. Use of recombinant BP26 protein for serodiagnosis of brucellosis. Clin Diagn Lab Immunol. 1997;4(6):711-716.

[50] Foster JT, Price LB, Beckstrom-Sternberg SM, et al. Genotyping of Brucella abortus isolates from wildlife and livestock in the Greater Yellowstone Area. J Clin Microbiol. 2008;46(12):3986-3992.